TABLE 3.
Results of the quantile mixed models aiming at identifying predictors of antibody and T cell-mediated responses to BNT162b2 vaccine against SARS-CoV-2 in liver and lung transplant recipients.
| Response variable | Predictors | OLT recipients | LUT recipients | ||
|---|---|---|---|---|---|
| β (95% CI) | p-value | β (95% CI) | p-value | ||
| Anti-SARS-CoV-2 Ig (IU/mL) | Intercept | 564 (−589; 1,717) | 0.330 | 1,372 (−924; 3,669) | 0.236 |
| Male sex | 152 (−670; 975) | 0.711 | 222 (−817; 1,261) | 0.670 | |
| Age (years) a | −4 (−34; 27) | 0.799 | −13 (−42; 16) | 0.364 | |
| Time from transplantation | 8 (−25; 42) | 0.630 | −6 (−191; 179) | 0.951 | |
| Prior SARS-CoV-2 infection | 7,351 (5,704; 8,997) | <0.0001 | 6,874 (3,668; 10,080) | <0.0001 | |
| Diabetes | −155 (−970; 659) | 0.704 | −674 (−2,248; 900) | 0.394 | |
| Chronic renal failure | −678 (−1,531; 174) | 0.116 | −917 (−2,091; 258) | 0.123 | |
| Cancer | 301 (−562; 1,164) | 0.487 | 1,129 (−1,476; 3,734) | 0.388 | |
| Mycophenolate Mofetil/Azathioprine | −562 (−1,403; 279) | 0.186 | 975 (−27; 1,977) | 0.056 | |
| Triple immunosuppression | −645 (−2,302; 1,012) | 0.438 | −960 (−2,560; 641) | 0.234 | |
| Vaccine dose (post 3rd vs. 2nd dose) | 4,976 (4,354; 5,597) | <0.0001 | 2,345 (1,380; 3,309) | <0.0001 | |
| INF-γ SFU (per 250,000 PBMC) | Intercept | 7.4 (−3.8; 18.5) | 0.192 | 7.6 (−7.9; 23.1) | 0.331 |
| Male sex | 2.9 (−7.6; 13.4) | 0.580 | 2.6 (−2.8; 8) | 0.333 | |
| Age (years) a | −0.1 (−0.4; 0.2) | 0.492 | −0.2 (−0.4; 0) | 0.020 | |
| Time from transplantation | 0.1 (−0.6; 0.8) | 0.802 | −0.1 (−1; 0.8) | 0.812 | |
| Prior SARS-CoV-2 infection | 24.5 (13.4; 35.7) | <0.0001 | |||
| Diabetes | −0.1 (−10; 9.9) | 0.988 | 0.5 (−10.6; 11.5) | 0.933 | |
| Chronic renal failure | −11.2 (−21.3; −1.1) | 0.031 | −3.3 (−11.4; 4.8) | 0.419 | |
| Cancer | 6.6 (−4.6; 17.7) | 0.245 | 6.1 (−7.1; 19.2) | 0.359 | |
| Mycophenolate Mofetil Azathioprine | −2.6 (−11.5; 6.4) | 0.567 | 5.1 (−1.8; 12) | 0.141 | |
| Triple immunosuppression | −9 (−18.5; 0.5) | 0.064 | −1.7 (−7.5; 4.1) | 0.550 | |
| Vaccine dose (post 3rd vs. 2nd dose) | 21.2 (14.4; 27.9) | <0.0001 | 5.8 (1.3; 10.4) | 0.013 | |
β, regression coefficients; CI, Confidence interval; OLT, Orthotopic liver transplant; LUT, lung transplant.
a
Centred to the mean. Mean ages among the OLT recipients were 63.9 years in the anti-SARS-CoV-2 Ig analysis and 63.5 years in the INF-γ analysis. Mean ages among the LUT recipients were 45.1 years in the anti-SARS-CoV-2 Ig analysis and 45.3 years in the INF-γ analysis.